1. Home
  2. PRGO vs XERS Comparison

PRGO vs XERS Comparison

Compare PRGO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perrigo Company plc

PRGO

Perrigo Company plc

HOLD

Current Price

$10.61

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.78

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRGO
XERS
Founded
1887
2005
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
PRGO
XERS
Price
$10.61
$8.78
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$19.33
$10.83
AVG Volume (30 Days)
3.9M
2.3M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
10.28%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
$800,000.00
$49,590,000.00
Revenue This Year
N/A
$34.37
Revenue Next Year
$1.02
$22.86
P/E Ratio
N/A
$867.50
Revenue Growth
N/A
142.67
52 Week Low
$9.23
$4.87
52 Week High
$28.44
$10.08

Technical Indicators

Market Signals
Indicator
PRGO
XERS
Relative Strength Index (RSI) 51.07 72.51
Support Level $10.37 $6.86
Resistance Level $11.81 $9.02
Average True Range (ATR) 0.55 0.37
MACD 0.06 0.01
Stochastic Oscillator 51.48 82.92

Price Performance

Historical Comparison
PRGO
XERS

About PRGO Perrigo Company plc

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: